<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02412098</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-372-1048</org_study_id>
    <secondary_id>2014-005266-30</secondary_id>
    <nct_id>NCT02412098</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function</brief_title>
  <official_title>A Phase 1, Open-Label, Parallel-Group, Adaptive, Single Dose Study to Evaluate the Pharmacokinetics of GS-6615 in Subjects With Normal and Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the pharmacokinetic (PK) profile of oral
      eleclazine and its metabolite, GS-623134, in participants with normal and impaired hepatic
      function. Participants in the healthy control group will be matched to participants with
      impaired hepatic function by age (± 5 years), gender, and body mass index (± 10%).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 19, 2015</start_date>
  <completion_date type="Actual">April 22, 2016</completion_date>
  <primary_completion_date type="Actual">April 22, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
    <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
    <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of Eleclazine</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
    <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
    <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>First dose date up to 31 days</time_frame>
    <description>Treatment-emergent adverse events (AEs) are defined as one or both of the following:
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.
Any AEs leading to premature discontinuation of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Clinical Laboratory Abnormalities</measure>
    <time_frame>First dose date up to 31 days</time_frame>
    <description>Treatment-emergent laboratory abnormalities reported as an adverse event (AE) or serious adverse event (SAE) are presented. Laboratory abnormalities that required medical or surgical intervention or led to study drug interruption, modification, or discontinuation were recorded as an AE or SAE, as applicable, and are reported here. Laboratory abnormalities without clinical significance were not recorded as AEs or SAEs and therefore, are not being reported.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Long QT Syndrome</condition>
  <arm_group>
    <arm_group_label>Moderate Hepatic Impairment (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe Hepatic Impairment (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Hepatic Impairment (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mild hepatic impairment and matched healthy controls will receive a single dose of eleclazine 30 mg (5 x 6 mg tablets).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eleclazine</intervention_name>
    <description>Eleclazine tablets administered orally</description>
    <arm_group_label>Mild Hepatic Impairment (Cohort 3)</arm_group_label>
    <arm_group_label>Moderate Hepatic Impairment (Cohort 1)</arm_group_label>
    <arm_group_label>Severe Hepatic Impairment (Cohort 2)</arm_group_label>
    <other_name>GS-6615</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        All participants:

          -  Be a nonsmoker or consume &lt; 20 cigarettes per day

          -  Have a calculated body mass index (BMI) from 18 to 36 kg/m^2, inclusive, at study
             screening

          -  Have a creatinine clearance (CrCl) ≥ 60 mL/min (using the Cockcroft-Gault method)
             based on serum creatinine and actual body weight as measured at screening

          -  Have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that
             are considered clinically insignificant by the investigator

          -  Screening labs within defined thresholds

        Participants with mild, moderate, or severe hepatic impairment must also meet the following
        additional inclusion criteria:

          -  Must have diagnosis of chronic (&gt; 6 months), stable hepatic impairment with no
             clinically significant changes within 3 months (90 days) prior to study drug
             administration (Day 1)

          -  Individuals with severe hepatic impairment must have a score on the
             Child-Pugh-Turcotte scale of 10-15 at screening. If an individual's score changes
             during the course of the study, the score at screening will be used for
             classification.

          -  Individuals with moderate hepatic impairment must have a score on the
             Child-Pugh-Turcotte scale of 7-9 at screening. If an individual's score changes during
             the course of the study, the score at Screening will be used for classification.

          -  Individuals with mild hepatic impairment must have a score on the Child-Pugh-Turcotte
             scale of 5-6 at screening. If an individual's score changes during the course of the
             study, the score at screening will be used for classification.

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  History of meningitis or encephalitis, epilepsy, seizures, migraines, tremors,
             myoclonic jerks, narcolepsy, obstructive sleep apnea, anxiety, syncope, head injuries
             or a family history of seizures

          -  Presence or history of cardiovascular disease (including history of myocardial
             infarction based on ECG and/or clinical history, any history of ventricular
             tachycardia, congestive heart failure, cardiomyopathy, or left ventricular ejection
             fraction &lt; 40%), cardiac conduction abnormalities, a family history of Long QT
             Syndrome, or unexplained death in an otherwise healthy individual between the ages of
             1 and 30 years

          -  Syncope, palpitations, or unexplained dizziness

          -  Implanted defibrillator or pacemaker

          -  Are unable to comply with study requirements or are otherwise believed, by the study
             investigator, to be inappropriate for study participation for any reason

        Participants with mild, moderate, or severe hepatic impairment must also meet the following
        additional exclusion criteria:

          -  Active hepatitis B virus (HBV) infection. Individuals who have HBsAg are ineligible

          -  Requires paracentesis &gt; 1 time per month

          -  Severe (grade 3 or 4) encephalopathy as judged by the investigator

          -  History of gastric or esophageal variceal bleeding within the past 6 months and for
             which varices have not been adequately treated with medication and/or surgical
             procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>New Zealand</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Moldova, Republic of</country>
  </removed_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2015</study_first_posted>
  <results_first_submitted>May 31, 2019</results_first_submitted>
  <results_first_submitted_qc>May 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2019</results_first_posted>
  <last_update_submitted>May 31, 2019</last_update_submitted>
  <last_update_submitted_qc>May 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatic Impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Long QT Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in United States, Romania, Germany, and New Zealand. The first participant was screened on 19 March 2015. The last study visit occurred on 22 April 2016.</recruitment_details>
      <pre_assignment_details>91 participants were screened. No participants were enrolled in the severe hepatic impairment (cohort 2) arm.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Moderate Hepatic Impairment (Cohort 1)</title>
          <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Mild Hepatic Impairment (Cohort 3)</title>
          <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set included all enrolled participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Moderate Hepatic Impairment (Cohort 1)</title>
          <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Mild Hepatic Impairment (Cohort 3)</title>
          <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="21"/>
            <count group_id="B4" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="5.3"/>
                    <measurement group_id="B2" value="57" spread="8.9"/>
                    <measurement group_id="B3" value="55" spread="6.9"/>
                    <measurement group_id="B4" value="56" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine</title>
        <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
        <population>PK Analysis Set included all enrolled participants who received at least one dose of eleclazine and had at least one evaluable PK concentration value reported by the PK laboratory for the corresponding analyte. Healthy control participants may participate in more than one cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (Cohort 1)</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment (Cohort 3)</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for Cohort 1)</title>
            <description>Normal hepatic function (matched control for Cohort 1) included participants that served as controls for participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Control for Cohort 3)</title>
            <description>Normal hepatic function (matched control for Cohort 3) included participants that served as controls for participants with mild hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>PK (Pharmacokinetic) Parameter: AUCinf of Eleclazine</title>
          <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
          <population>PK Analysis Set included all enrolled participants who received at least one dose of eleclazine and had at least one evaluable PK concentration value reported by the PK laboratory for the corresponding analyte. Healthy control participants may participate in more than one cohorts.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42503.2" lower_limit="23983.8" upper_limit="75322.7"/>
                    <measurement group_id="O2" value="50064.7" lower_limit="31758.4" upper_limit="78923.2"/>
                    <measurement group_id="O3" value="57795.9" lower_limit="37994.2" upper_limit="87917.5"/>
                    <measurement group_id="O4" value="39173.2" lower_limit="23050.5" upper_limit="66573.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>An analysis of variance (ANOVA) appropriate for a parallel design was fit to the natural logarithmic transformation of eleclazine AUCinf.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Geometric Least Square Mean (GLSM) Ratio</param_type>
            <param_value>73.54</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>41.92</ci_lower_limit>
            <ci_upper_limit>129.01</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of AUCinf in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>An analysis of variance (ANOVA) appropriate for a parallel design was fit to the natural logarithmic transformation of eleclazine AUCinf.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>127.80</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>73.57</ci_lower_limit>
            <ci_upper_limit>222.01</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of AUCinf in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)</title>
        <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
        <population>Participants in the PK Analysis Set with available data were analyzed. Healthy control participants may participate in more than one cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (Cohort 1)</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment (Cohort 3)</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for Cohort 1)</title>
            <description>Normal hepatic function (matched control for Cohort 1) included participants that served as controls for participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Control for Cohort 3)</title>
            <description>Normal hepatic function (matched control for Cohort 3) included participants that served as controls for participants with mild hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCinf of GS-623134 (Metabolite of Eleclazine)</title>
          <description>AUCinf was defined as the concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time).</description>
          <population>Participants in the PK Analysis Set with available data were analyzed. Healthy control participants may participate in more than one cohorts.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1880.0" lower_limit="980.5" upper_limit="3604.4"/>
                    <measurement group_id="O2" value="1983.2" lower_limit="1238.3" upper_limit="3176.0"/>
                    <measurement group_id="O3" value="2326.2" lower_limit="1497.0" upper_limit="3614.9"/>
                    <measurement group_id="O4" value="2697.4" lower_limit="2023.1" upper_limit="3596.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA appropriate for a parallel design was fit to the natural logarithmic transformation of GS-623134 AUCinf.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>80.82</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>45.11</ci_lower_limit>
            <ci_upper_limit>144.79</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of AUCinf in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>73.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>47.83</ci_lower_limit>
            <ci_upper_limit>113.02</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of AUCinf in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Cmax of Eleclazine</title>
        <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
        <population>Participants in the PK Analysis Set were analyzed. Healthy control participants may participate in more than one cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (Cohort 1)</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment (Cohort 3)</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for Cohort 1)</title>
            <description>Normal hepatic function (matched control for Cohort 1) included participants that served as controls for participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Control for Cohort 3)</title>
            <description>Normal hepatic function (matched control for Cohort 3) included participants that served as controls for participants with mild hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax of Eleclazine</title>
          <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
          <population>Participants in the PK Analysis Set were analyzed. Healthy control participants may participate in more than one cohorts.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="214.9" lower_limit="169.4" upper_limit="272.5"/>
                    <measurement group_id="O2" value="338.1" lower_limit="283.6" upper_limit="403.1"/>
                    <measurement group_id="O3" value="322.9" lower_limit="279.4" upper_limit="373.1"/>
                    <measurement group_id="O4" value="331.3" lower_limit="273.1" upper_limit="401.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA appropriate for a parallel design was fit to the natural logarithmic transformation of eleclazine Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>66.55</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>53.33</ci_lower_limit>
            <ci_upper_limit>83.04</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of Cmax in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA appropriate for a parallel design was fit to the natural logarithmic transformation of eleclazine Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>102.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.03</ci_lower_limit>
            <ci_upper_limit>125.45</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of Cmax in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)</title>
        <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
        <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 14, 24, 36, 48, 72, 96, 120 hours on Day 1 and approximately the same time in the morning as predose of Day 1 on Days 15, 29, 43, and 57</time_frame>
        <population>Participants in the PK Analysis Set with available data were analyzed. Healthy control participants may participate in more than one cohorts.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment (Cohort 1)</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment (Cohort 3)</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function (Matched Control for Cohort 1)</title>
            <description>Normal hepatic function (matched control for Cohort 1) included participants that served as controls for participants with moderate hepatic impairment.</description>
          </group>
          <group group_id="O4">
            <title>Normal Hepatic Function (Matched Control for Cohort 3)</title>
            <description>Normal hepatic function (matched control for Cohort 3) included participants that served as controls for participants with mild hepatic impairment.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax of GS-623134 (Metabolite of Eleclazine)</title>
          <description>Cmax was defined as the maximum observed concentration of drug in plasma.</description>
          <population>Participants in the PK Analysis Set with available data were analyzed. Healthy control participants may participate in more than one cohorts.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.2" upper_limit="7.7"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.6" upper_limit="11.4"/>
                    <measurement group_id="O3" value="6.5" lower_limit="5.0" upper_limit="8.4"/>
                    <measurement group_id="O4" value="10.2" lower_limit="7.0" upper_limit="15.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>ANOVA appropriate for a parallel design was fit to the natural logarithmic transformation of GS-623134 Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>76.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>50.65</ci_lower_limit>
            <ci_upper_limit>114.77</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of Cmax in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>ANOVA appropriate for a parallel design was fit to the natural logarithmic transformation of GS-623134 Cmax.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>GLSM Ratio (%)</param_type>
            <param_value>71.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>44.59</ci_lower_limit>
            <ci_upper_limit>113.25</ci_upper_limit>
            <estimate_desc>A 90% CI was constructed for the GLSM ratio of Cmax in the hepatic impairment group versus matched control.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Treatment-Emergent Adverse Events</title>
        <description>Treatment-emergent adverse events (AEs) are defined as one or both of the following:
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.
Any AEs leading to premature discontinuation of study drug.</description>
        <time_frame>First dose date up to 31 days</time_frame>
        <population>Safety Analysis Set included all enrolled participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Treatment-Emergent Adverse Events</title>
          <description>Treatment-emergent adverse events (AEs) are defined as one or both of the following:
Any AEs with an onset date on or after the study drug start date and no later than 30 days after permanent discontinuation of study drug.
Any AEs leading to premature discontinuation of study drug.</description>
          <population>Safety Analysis Set included all enrolled participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Clinical Laboratory Abnormalities</title>
        <description>Treatment-emergent laboratory abnormalities reported as an adverse event (AE) or serious adverse event (SAE) are presented. Laboratory abnormalities that required medical or surgical intervention or led to study drug interruption, modification, or discontinuation were recorded as an AE or SAE, as applicable, and are reported here. Laboratory abnormalities without clinical significance were not recorded as AEs or SAEs and therefore, are not being reported.</description>
        <time_frame>First dose date up to 31 days</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Moderate Hepatic Impairment</title>
            <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Mild Hepatic Impairment</title>
            <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Normal Hepatic Function</title>
            <description>Participants with normal hepatic function received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Clinical Laboratory Abnormalities</title>
          <description>Treatment-emergent laboratory abnormalities reported as an adverse event (AE) or serious adverse event (SAE) are presented. Laboratory abnormalities that required medical or surgical intervention or led to study drug interruption, modification, or discontinuation were recorded as an AE or SAE, as applicable, and are reported here. Laboratory abnormalities without clinical significance were not recorded as AEs or SAEs and therefore, are not being reported.</description>
          <population>Participants in the Safety Analysis Set were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Creatinine Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma-glutamyltransferase Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose date up to 31 days</time_frame>
      <desc>Safety Analysis Set included all enrolled participants who received at least one dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Moderate Hepatic Impairment</title>
          <description>Participants with moderate hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Mild Hepatic Impairment</title>
          <description>Participants with mild hepatic impairment received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Normal Hepatic Function</title>
          <description>Participants with normal hepatic function received a single dose of eleclazine 30 mg (5 x 6 mg tablets) on Day 1.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Electrocardiogram PR prolongation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

